Our lab is very interested in skin diseases including cancer. We investigate the molecular causes for these diseases in order to design effective therapies. This is done in close proximity to patients where our goal is to translate the discoveries as fast as possible to healthcare. We have contributed to understand the role of EMLIN-1 in the progression of melanoma metastasis. We also have participated in a broad study about the consequences of COVID-19 in melanoma and cutaneous squamous cell carcinoma tumor burden. Some other studies include some diagnostic techniques in leishmaniasis and the molecular characterization in inflammatory processes such as lupus.

Group Leader
Juan Angel Recio Conde

Principal Investigator (PI)
Vicente García-Patos Briones

Researchers
KImberley McGrail, Carlos González Cruz

PhD Students
Paula Martínez Granado, Berta Ferrer Fabregas, Yuxin Ding

8

PUBLICATIONS

33

IMPACT FACTOR

4.16

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Amor López A, Mazariegos MS, Capuano A, Ximénez-Embún P, Hergueta-Redondo M, Recio JÁ, Muñoz E, Al-Shahrour F, Muñoz J, Megías D, Doliana R, Spessotto P, Peinado H.
Inactivation of EMILIN-1 by Proteolysis and Secretion in Small Extracellular Vesicles Favors Melanoma Progression and Metastasis.
Int J Mol Sci. 2021 Jul 9;22(14):7406
DOI: 10.3390/ijms22147406.
IF: 5.92

Silgado A, Armas M, Sánchez-Montalvá A, Goterris L, Ubals M, Temprana-Salvador J, Aparicio G, Chicharro C, Serre-Delcor N, Ferrer B, Molina I, García-Patos V, Pumarola T, Sulleiro E.
Changes in the microbiological diagnosis and epidemiology of cutaneous leishmaniasis in real-time PCR era: A six-year experience in a referral center in Barcelona.
PLoS Negl Trop Dis. 2021 Nov 10;15(11):e0009884.
DOI: 10.1371/journal.pntd.0009884.
IF: 4.41

Sandra Domingo , Cristina Solé, Teresa Moliné, Berta Ferrer, Josefina Cortés-Hernández
Thalidomide Exerts Anti-Inflammatory Effects in Cutaneous Lupus by Inhibiting the IRF4/NF-B and AMPK1/mTOR Pathways.
Biomedicines 2021 Dec 7;9(12):1857.
DOI: 10.3390/biomedicines9121857.
IF: 6.08

Antonio Tejera-Vaquerizo, Sabela Paradela, Agusti Toll, Jorge Santos-Juanes, Ane Jaka, Alba López, Javier Cañueto, Àlvaro Bernal, Isabel Villegas-Romero, Carla Ferrándiz-Pulido, Héctor Perandones, David Moreno-Ramírez, Carolina Domínguez-Mahamud, Rafael Salido-Vallejo, Onofre Sanmartin, Francisco M Almazán-Fernández, Pedro Rodríguez-Jiménez, José Bañuls, Sebastian Podlipnik, Alejandra Sandoval-Clavijo, Aram Boada, Beatriz García-Bracamonte, Sara Palencia, David Revilla-Nevreda, Enara Reola-Ramírez, María Del Carmen Gómez-Mateo, Mario Linares-Barrios, David Jiménez-Gallo, Carlos González-Cruz, Elia Samaniego, María Navedo-de Las Heras, Rosa Taberner, Teresa Ródenas-Herranz, Carmen García-Donoso, Susana Puig, Eduardo Nagore
Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma.
Acta Derm Venereol . 2021 Aug 25;101(8):adv00525.
DOI: 10.2340/00015555-3890.
IF: 4.44

Ubals M, Bosch-Nicolau P, Sánchez-Montalvá A, Salvador F, Aparicio-Español G, Sulleiro E, Silgado A, Soriano-Arandes A, Espiau M, Ferrer B, Pou D, Treviño B, Molina I, García-Patos V.
Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
Pathogens. 2021 Sep 28;10(10):1253.
DOI: 10.3390/pathogens10101253.
IF: 3.49

Oncogene-mediated intratumoral immune-cell populations at different organs as biomarkers of immunotherapy response
Principal Investigator: Juan A. Recio
Agency: FIS- ISCIII
Funding: 341,220.00 €
Period: 2021-2023

Modulation of melanoma-stroma interactions using a rationally-designed nanomedicine combining BRAFi-, MEKi- and immune-therapies
Principal Investigator: R.Satchi-Fainaro. Juan A. Recio H.Florindo J.Steffen
Funding: 375,000 €
Period: 2018-2021

Study of the cooperation of the stress pathway (MAPK14) in melanoma development, progression and intra-tumoral immune response for therapeutic purposes
Principal Investigator: Juan a. Recio
Agency: FIS-ISCIII
Funding: 142,000.00 €
Period: 2018-2021

Distinct routes of metastatic dissemination in different melanoma subtypes:Implications in the validation of new tumor biomarkers and therapeutic targets
Principal Investigator: M. Soengas, Juan A Recio., S. Puig, JL Rodriguez Peral, H Peinado and J Piulats
Agency: Asociacion Española contra el Cancer (AECC)
Funding: 1,200,000€
Period: 2015-2021

Oncology

Research Areas